ISCOM technology-based Matrix M™ adjuvant: Success in future vaccines relies on formulation

Expert Review of Vaccines

Volumn 10, Issue 4, 2011, Pages 401-403

  Lövgren Bengtsson, Karin ^a   Morein, Bror ^b   Osterhaus, Albert Dme ^c,d  

^a Isconova AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ViroClinics Biosciences BV   (Netherlands)

Author keywords

ISCOM; Matrix M; Quillaja saponaria Molina; saponin; Th1 Th2; vaccine adjuvant

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; IMMUNOLOGICAL ADJUVANT; ISCOM; MATRIX M; NANOPARTICLE; RECOMBINANT DNA; SAPONIN; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; BINDING AFFINITY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; EDITORIAL; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; QUILLAJA; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; HUMANS; ISCOMS; VACCINES;

EID: 79955113278     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.25     Document Type: Editorial

References (11)

1. Rajput ZI, Hu S, Xiao C, Arijo AG. Adjuvant effects of saponins on animal immune responses. J. Zhejiang Univ. Sci. B 8(3), 153-161 (2007).
2. Waite DC, Jacobson EW, Ennis FA et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19, 3957-3967 (2001). (Pubitemid 32566320)
3. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. ISCOM, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308, 457-460 (1984). (Pubitemid 14130919)
4. Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (ISCOMs).Biotechnol. Appl. Biochem. 10, 161-172 (1988).
5. Morein B, Lövgren Bengtsson K. Functional aspects of ISCOMs. Immunol. Cell. Biol. 76(4), 295-299 (1998). (Pubitemid 28352759)
6. Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky B. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope proteins in ISCOMs. Nature 344, 873-875 (1990).
7. van Binnendijk RS, van Baalen CA, Poelen MC et al. Measles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 176(11), 119-128 (1992).
8. Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ. Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix. Vaccine 28(43), 6989-6996 (2010).
9. McKenzie A, Watt M, Gittleson C. ISCOMATRIXTM vaccines: safety in human clinical studies. Hum. Vaccin. 6(3), 237-246 (2010).
10. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27(52), 7367-7376 (2009).
11. Cox R. H5N1 virosome vaccine development. Presented at: 6th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. Geneva, Switzerland, 18-19 February 2010.